Abstract
We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive because of declining disease burden. We estimate catch-up vaccination of 1 year old children could be cost-effective, incremental on the infant programme with a vaccine price of ≤£8 per dose. Extending vaccination to 2 year olds could only be cost-effective (incremental on infant and 1 year old catch-up) with a vaccine price of ≤£3 per dose and was not cost-effective in sensitivity analyses with more conservative vaccine assumptions. Extending catch-up further to 3-4 year olds was not cost-effective. Employing the current criteria for assessing vaccines, our models suggest that even with low vaccine prices only catch-up vaccination in 1 year old children could be cost-effective, when considered incrementally on the infant programme.
Original language | English |
---|---|
Pages (from-to) | 208-211 |
Number of pages | 4 |
Journal | Vaccine |
Volume | 35 |
Issue number | 2 |
Early online date | 5 Dec 2016 |
DOIs | |
Publication status | Published - 5 Jan 2017 |
Keywords
- Catch-up
- Cost-effectiveness
- Group B
- Meningococcal disease
- Vaccination
Fingerprint Dive into the research topics of 'Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England'. Together they form a unique fingerprint.
Profiles
-
Dr Hannah Christensen
- Bristol Medical School (PHS) - Senior Lecturer in Infectious Disease Mathematical Modelling
- Bristol Population Health Science Institute
- Health Protection Research Unit (HPRU)
- Centre for Academic Primary Care
Person: Academic , Member